Form 10-K aTYR PHARMA INC For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
aTyr Pharma (LIFE) PT Lowered to $16 at RBC Capital
March 15, 2024 6:39 AM EDTRBC Capital analyst Kennan MacKay lowered the price target on aTyr Pharma (NASDAQ: LIFE) to $16.00 (from $19.00) while maintaining a Outperform rating.
The analyst comments "From LIFEs YE call, Early Access Program demand underscores the enthusiasm across sites as the ph.III EFZO-FIT... More
